Home > Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction, Europol. (2018) Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union. 83 p. 10.2810/716236 I ISBN 978-92-9497-245-3

[img]
Preview
PDF (Risk assessment ADB-CHMINACA)
1MB

This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. Synthetic cannabinoids such as ADB-CHMINACA are functionally similar to Δ9 -tetrahydrocannabinol (THC), the major psychoactive principle of cannabis. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.

Table of contents:
· Foreword
· EMCDDA actions on monitoring and responding to new drugs
Europol–EMCDDA Joint Report on ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) — a summary
· Risk Assessment Report on a new psychoactive substance: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
· Technical report on N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
· Participants of the risk assessment meeting, 7-8 November 2017


Item Type:Evidence resource
Drug Type:Cannabis, New psychoactive substance
Intervention Type:AOD disorder harm reduction
Date:May 2018
Pages:83 p.
Publisher:Publications Office of the European Union
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction, Europol
Place of Publication:Luxembourg
EndNote:View
Related URLs:
Subjects:B Drugs and alcohol substances > Cannabis product (synthetic cannabinoids)
B Drugs and alcohol substances > New (novel) psychoactive substances
J Health care, prevention and rehabilitation > Risk and needs assessment > Risk assessment
VA Geographic area > Europe

Repository Staff Only: item control page